Company intelligence / Profile preview

Huahui Health

Beijing, Beijing, Chinahuahuihealth.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Huahui Health has developed a robust pipeline of innovative therapies targeting liver diseases—especially hepatitis B and D—leveraging the discovery of NTCP as a viral entry receptor. Its lead asset, Libevitug (HH‑003), an anti-preS1 human monoclonal antibody, received FDA Breakthrough Therapy Designation for chronic HDV. The company also develops candidates for solid tumors using advanced antibody engineering. Early clinical results show promise in achieving functional cures for hepatitis B/D with ongoing trials in China and globally.

Therapeutic areas: OncologyInfectious Diseases
Modalities: monoclonal antibodies (mAbs)small moleculesantibody drug conjugates (ADCs)biological products
Industry: Biotech

Drug pipeline

13 assets

HH-120

12 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Huahui Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huahui Health.

Explore the full profile